Krystal Biotech
KRYS
264 hedge funds and large institutions have $4.35B invested in Krystal Biotech in 2024 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 95 increasing their positions, 97 reducing their positions, and 52 closing their positions.
72% more call options, than puts
Call options by funds: $63.3M | Put options by funds: $36.8M
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
2% less repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 97
1.87% less ownership
Funds ownership: 98.44% → 96.57% (-1.9%)
7% less funds holding
Funds holding: 283 → 264 (-19)
15% less capital invested
Capital invested by funds: $5.15B → $4.35B (-$796M)
29% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$25.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$12.6M |
| 3 |
Citigroup
New York
|
+$11.5M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$11.3M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
+$9.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$35.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$30.8M |
| 3 |
Jennison Associates
New York
|
-$18.9M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$16M |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$14.5M |
KRYS Hedge Fund Activity: Q4 2024 in Review
264 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q4 2024, worth a combined $4.35B — down 15% from $5.15B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of KRYS and 37 opened new positions — a net loss of 15 holders — while 97 trimmed existing stakes and 95 added.
The largest buyer was Soleus Capital Management, adding an estimated $25.1M. The largest seller was Frazier Life Sciences Management, cutting an estimated $35.5M.
- 264 institutional investors held Krystal Biotech (KRYS) as of Q4 2024, down from 283 in Q3 2024.
- Funds reported $4.35B of Krystal Biotech stock for Q4 2024, down 15% quarter-over-quarter.
- 37 funds opened new Krystal Biotech positions in Q4 2024 and 52 closed out, a net change of -15 holders.
- The largest Krystal Biotech buyer in Q4 2024 was Soleus Capital Management, an estimated $25.1M added.
- The largest Krystal Biotech seller in Q4 2024 was Frazier Life Sciences Management, an estimated $35.5M sold.
Based on aggregated 13F filings for Q4 2024.